Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer
Table 2
Ki67 labeling index (%) and cleaved caspase 3 (CC3) at baseline (before anastrozole) and surgery (after anastrozole) on the 20 patients who completed the study.
Statistic
Patients
value
Ki67 labeling index (%)
Baseline
Mean (std)
33.2 (17.6)
Median (10p, 90p)
31.7 (13.2, 61.8)
End of study
Mean (std)
19.1 (21.2)
Median (10p, 90p)
12.1 (0.7, 55.8)
% change
Mean (std)
−48.8 (40.1)
Median (10p, 90p)
−55.8 (−97.5, 10.1)
= 0.001
Absolute change
Mean (std)
−14.1 (17.5)
Median (10p, 90p)
−12.2 (−35.6, 6.2)
< 0.001
Cleaved caspase 3 (CC3)
Baseline
Mean (std)
7.7 (7.4)
Median (10p, 90p)
5.9 (1.3, 16.3)
End of study
Mean (std)
4.8 (3.6)
Median (10p, 90p)
3.1 (1.2, 9.8)
% change
Mean (std)
−10.5 (67.7)
Median (10p, 90p)
−25.5 (−76.9, 66.7)
= 0.17
Absolute change
Mean (std)
−2.9 (6.3)
Median (10p, 90p)
−1.6 (−11.2, 1.1)
= 0.007
10p = 10th percentile; 90p = 90th percentile; value = Wilcoxon rank sum; std = standard deviation.
